Huo Rongxiu, Yang Yanting, Wei Chengcheng, Huo Xiaocong, Meng Danli, Yang Yang, Huang Yijia, Huang Rongjun, Lin Jinying, Huang Xinxiang
Department of Rheumatology and Immunology, Guangxi Academy of Medical Sciences, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi Zhuang Autonomous Region 530016, P.R. China.
Int J Mol Med. 2025 Feb;55(2). doi: 10.3892/ijmm.2024.5471. Epub 2024 Dec 13.
Antiphospholipid syndrome (APS) is an autoimmune disease characterized by arterial and/or venous thrombosis, pathological pregnancies and persistent antiphospholipid antibodies. The occurrence and development of APS are complex and associated with immune disorders, with its prognosis remaining uncertain. Owing to its pathogenesis, anticoagulation therapy is the primary treatment for patients with APS. In recent years, with increased attention on APS, research on its treatment strategies has flourished, and preclinical and clinical relevance studies are being conducted to re‑evaluate the mechanism of action of existing drugs and to develop new drugs. Recent evidence suggests that vitamin D (VD) may help improve immune disorders in patients with APS by regulating the balance between immune cells. In this review, the potential mechanistic role of VD in APS protection was discussed, highlighting the potential effects of VD as a promising adjuvant treatment option for APS.
抗磷脂综合征（APS）是一种自身免疫性疾病，其特征为动脉和/或静脉血栓形成、病理性妊娠以及持续性抗磷脂抗体。APS的发生和发展较为复杂，与免疫紊乱相关，其预后仍不确定。由于其发病机制，抗凝治疗是APS患者的主要治疗方法。近年来，随着对APS关注度的提高，其治疗策略的研究蓬勃发展，正在进行临床前和临床相关性研究，以重新评估现有药物的作用机制并开发新药。最近的证据表明，维生素D（VD）可能通过调节免疫细胞之间的平衡来帮助改善APS患者的免疫紊乱。在这篇综述中，讨论了VD在APS保护中的潜在机制作用，强调了VD作为APS一种有前景的辅助治疗选择的潜在效果。
